Published in Oncogene on October 20, 2008
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell (2011) 1.91
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol (2013) 1.90
Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem (2009) 1.45
A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency. Mol Cell Proteomics (2010) 1.41
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov (2011) 1.12
A systematic protocol for the characterization of Hsp90 modulators. Bioorg Med Chem (2010) 1.04
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem (2009) 1.02
Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics (2011) 0.97
Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype. Syst Synth Biol (2009) 0.94
Molecular cochaperones: tumor growth and cancer treatment. Scientifica (Cairo) (2013) 0.92
Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. Mol Cell Biol (2013) 0.88
Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene (2013) 0.88
Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer (2011) 0.87
The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics. J Biol Chem (2011) 0.87
Maximizing the Therapeutic Potential of HSP90 Inhibitors. Mol Cancer Res (2015) 0.86
Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions. J Biol Chem (2010) 0.86
E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells. Proc Natl Acad Sci U S A (2014) 0.84
Macrocyclic inhibitors of hsp90. Curr Top Med Chem (2010) 0.83
Phosphorylated and unphosphorylated serine 13 of CDC37 stabilize distinct interactions between its client and HSP90 binding domains. Biochemistry (2015) 0.82
A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor. PLoS One (2013) 0.82
Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells. Mol Cancer Ther (2010) 0.82
Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget (2014) 0.81
Correlation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37. Mol Med (2014) 0.79
BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability. Br J Cancer (2014) 0.79
Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget (2015) 0.78
Small Molecule Inhibitors to Disrupt Protein-protein Interactions of Heat Shock Protein 90 Chaperone Machinery. J Cancer Prev (2015) 0.78
Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease. Curr Top Med Chem (2016) 0.77
The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein. BMC Cancer (2012) 0.77
Heat shock protein 90: its inhibition and function. Philos Trans R Soc Lond B Biol Sci (2018) 0.77
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15. Invest New Drugs (2016) 0.76
Serine/threonine Kinase Unc-51 Like Kinase-1 (Ulk1) Phosphorylates the Co-chaperone Cdc37 and Thereby Disrupts the Stability of Cdc37 Client Proteins. J Biol Chem (2017) 0.75
Stability of the human Hsp90-p50Cdc37 chaperone complex against nucleotides and Hsp90 inhibitors, and the influence of phosphorylation by casein kinase 2. Molecules (2015) 0.75
Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation. J Biol Chem (2016) 0.75
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. Gastroenterology (2017) 0.75
HOP expression is regulated by p53 and RAS and characteristic of a cancer gene signature. Cell Stress Chaperones (2016) 0.75
The protein kinase complement of the human genome. Science (2002) 35.36
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol (2001) 6.10
Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem (2006) 5.82
Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A (2000) 4.55
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem (1999) 4.02
Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell (2002) 3.89
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci (2007) 3.74
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem (2002) 3.70
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A (2002) 3.54
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol (2005) 3.42
In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol (1998) 3.38
The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J (2008) 3.33
Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev (1996) 3.26
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res (2006) 3.10
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery. J Biol Chem (1998) 2.63
Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell (2006) 2.62
HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther (2002) 2.53
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell (2008) 2.49
Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem (2004) 2.45
The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell (2004) 2.36
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J Biol Chem (2002) 2.32
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Molecular chaperones and protein kinase quality control. Trends Cell Biol (2006) 2.05
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res (2005) 1.93
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol (1999) 1.83
Hsp90 and Cdc37 -- a chaperone cancer conspiracy. Curr Opin Genet Dev (2005) 1.78
SBA1 encodes a yeast hsp90 cochaperone that is homologous to vertebrate p23 proteins. Mol Cell Biol (1998) 1.75
Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J Biol Chem (2004) 1.71
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett (2004) 1.67
Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperones (2003) 1.64
Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem (2005) 1.60
Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2008) 1.48
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer (1998) 1.38
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res (2003) 1.35
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer (2008) 1.32
Cdc37 has distinct roles in protein kinase quality control that protect nascent chains from degradation and promote posttranslational maturation. J Cell Biol (2007) 1.29
C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest. EMBO J (2002) 1.29
Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem (2006) 1.29
Biochemical and structural studies of the interaction of Cdc37 with Hsp90. J Mol Biol (2004) 1.25
Interaction between Cdc37 and Cdk4 in human cells. Oncogene (1997) 1.25
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther (2007) 1.19
Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res (2007) 1.19
The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol (2000) 1.18
The Cdc37 protein kinase-binding domain is sufficient for protein kinase activity and cell viability. J Cell Biol (2002) 1.17
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther (2008) 1.16
Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation. Exp Cell Res (2005) 1.16
p50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry (2000) 1.13
Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene (2000) 1.13
Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem (2002) 1.00
Cdc37 maintains cellular viability in Schizosaccharomyces pombe independently of interactions with heat-shock protein 90. FEBS J (2005) 0.94
Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res (2003) 0.92
Analysis of mammalian Cdc37, a protein kinase targeting subunit of heat shock protein 90. Methods Enzymol (1997) 0.83
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Evaluation of the LMA Supreme in 100 non-paralysed patients. Anaesthesia (2009) 1.85
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
DT-diaphorase and cancer chemotherapy. Biochem Pharmacol (1992) 1.78
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Expression of gastrin in developing gastric adenocarcinoma. Br J Surg (2001) 1.65
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer (1998) 1.53
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem (2011) 1.44
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene (2000) 1.34
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer (1983) 1.33
The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun (1991) 1.32
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 1.30
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (2007) 1.27
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol (2001) 1.24
Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. Br J Cancer (1979) 1.23
Hsp90 inhibitors in the clinic. Handb Exp Pharmacol (2006) 1.21
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia (2010) 1.19
Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer (1999) 1.17
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia (2012) 1.16
Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol (1981) 1.14
Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1989) 1.13
Surprising specificity of PKR binding to delta agent genomic RNA. RNA (1997) 1.12
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer (1983) 1.11
Clinical studies with misonidazole. Br J Cancer Suppl (1978) 1.10
Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials (1980) 1.09
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer (1980) 1.08
De-regulation of the sonic hedgehog pathway in the InsGas mouse model of gastric carcinogenesis. Br J Cancer (2007) 1.08
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer (2005) 1.07
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol (1997) 1.07
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer (2005) 1.07
Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol (1994) 1.06
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer (1991) 1.06
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol (1983) 1.06
Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer (1994) 1.04
Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br J Cancer (2002) 1.03
Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol (1980) 1.02
Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res (2001) 1.02
The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. Br J Psychiatry (1974) 1.01
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys (1982) 1.01
DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer (1994) 1.00
Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer (2005) 0.99
Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol (1990) 0.99
K-ras mutations in patients with early colorectal cancers. Gut (1997) 0.99
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res (2001) 0.99
Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys (1989) 0.99
The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol (1992) 0.98
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. Br J Cancer (1982) 0.98
Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence. Br J Cancer (2002) 0.98
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Br J Cancer (1982) 0.96
A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem (2006) 0.96
Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes. Mol Pharmacol (1995) 0.96
Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol (1993) 0.95
Muscle fibre size in normal infants, children and adolescents. An autopsy study. J Neurol Sci (1971) 0.94
Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer (1999) 0.94
Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol (1989) 0.94
Phospholipid antitumor agents. Med Res Rev (1995) 0.93
Preclinical pharmacokinetics of benznidazole. Br J Cancer (1984) 0.93
Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys (1994) 0.93
Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol (1993) 0.92
Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol (1989) 0.92
Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol (1987) 0.92
Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis (1994) 0.91
Expression of CCKB/gastrin receptor isoforms in gastro-intestinal tumour cells. Int J Cancer (1998) 0.91
Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res (1990) 0.91
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer (1988) 0.91
A flow cytofluorimetric method for measuring enzyme reaction kinetics in intact cells. FEBS Lett (1977) 0.90
DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer (1992) 0.90
The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol (2003) 0.90
The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys (1992) 0.89
Drug interactions with misonidazole: effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice. Biochem Pharmacol (1980) 0.89
Infusional anthracyclines: is slower better? If so, why? Ann Oncol (1992) 0.89
Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. Cancer Chemother Pharmacol (1988) 0.87
The pharmacokinetics of misonidazole in the dog. Eur J Cancer (1979) 0.87
Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer (2002) 0.87
Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J Pharmacol Exp Ther (1993) 0.87
Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069. Int J Radiat Oncol Biol Phys (1984) 0.87
The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiat Res (1980) 0.87